Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16] - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points [19][24] - The blood products sector showed the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline, dropping by 16.04% [7][19][23] Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective human-relevant methods in drug development, which could enhance drug safety and lower costs [14][15] - The pharmaceutical sector's performance this week was marked by significant declines across various sub-sectors, with blood products being the only one to gain [19][23] Sub-sector Performance - Blood products increased by 4.06%, while medical outsourcing fell by 16.04%, indicating a significant divergence in performance among sub-sectors [7][19][23] - The medical device sector's P/E ratio is currently at 32.15, suggesting potential for valuation increases [27] - The IVD sector is also seen as having room for valuation growth, with a current P/E of 21.89 [33] Recommended and Benefiting Stocks - Recommended stocks include Microelectrophysiology, Maipu Medical, and Yingke Medical, among others [8][31][38] - Benefiting stocks from the FDA's policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17] Market Trends - The report highlights a structural investment opportunity in the pharmaceutical sector, driven by policy support and AI-enabled R&D [26] - The report notes that the medical device sector is expected to benefit from upcoming procurement policies and a low base effect in Q2 2025 [27][29]

Core Points - The China Securities Hong Kong Stock Connect Medical Comprehensive Index (932271) opened at 1310.24 points, showing a decline of 15.51% over the past month, an increase of 7.01% over the past three months, and a year-to-date increase of 1.58% [1] - The index is compiled based on the classification standards of the China Securities Index, reflecting the overall performance of different industry securities within the Hong Kong Stock Connect [1] - The top ten holdings of the index include Alibaba Health (14.23%), JD Health (14.01%), Sinopharm (12.15%), Weigao Group (7.98%), MicroPort Medical (5.06%), Ping An Good Doctor (4.48%), Shanghai Pharmaceuticals (4.05%), Jinxin Fertility (3.72%), Xianjian Technology (3.29%), and MicroPort Robotics-B (3.28%) [1] Industry Composition - The index's holdings are entirely from the Hong Kong Stock Exchange, with the pharmaceutical commercial sector accounting for 46.78%, medical services for 24.51%, medical consumables for 24.08%, medical devices for 3.70%, and in vitro diagnostics for 0.92% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments in case of special events affecting the index sample [2]

Core Viewpoint - The China Securities Index for the medical industry has shown a slight decline over the past month, quarter, and year-to-date, indicating a stable but slightly negative trend in the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry is currently at 566.67 points [1]. - Over the past month, the index has decreased by 0.49%, while it has seen a minimal decline of 0.02% over the past three months and year-to-date [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.12%) - Aier Eye Hospital (8.91%) - United Imaging Healthcare (7.39%) - Aimeike (3.93%) - Huatai Medical (3.48%) - New Industries (3.41%) - Yuyue Medical (3.12%) - Shanghai Pharmaceuticals (3.04%) - Meinian Onehealth (2.57%) - Jiuan Medical (2.39%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (57.38%) and the Shanghai Stock Exchange (42.62%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.29% - Medical Consumables: 23.16% - Pharmaceutical Commerce: 15.33% - Medical Services: 14.26% - In Vitro Diagnostics: 12.95% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Group 1 - China Telecom reported a net profit of 33.01 billion yuan for 2024, an increase of 8.4% year-on-year, with total revenue of 523.57 billion yuan, up 3.1% [1] - Minfeng Special Paper achieved a net profit of 72 million yuan, a year-on-year increase of 54.09%, despite a revenue decline of 9.82% to 1.46 billion yuan [2] - Kuaiji Elevator's net profit decreased by 8.46% to 132 million yuan, with total revenue falling by 4.93% to 1.58 billion yuan [3] Group 2 - Zhongjian Technology reported a net profit of 356 million yuan, up 23.16% year-on-year, with total revenue of 812 million yuan, an increase of 45.39% [4] - China Communication Technology announced the resignation of Vice President Zhao Xiaodong due to work changes [6] - Honghua Digital received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose the use of idle raised funds in a timely manner [8] Group 3 - Huazhong Shuanghe received a drug registration certificate for Gadobutrol injection, applicable for MRI examinations [10] - Ruihe Co. reported overdue loans totaling 15.2 million yuan due to slow accounts receivable turnover caused by a major client's debt crisis [12] - Lubo Chemical received a dividend of 76.5 million yuan from its subsidiary [13] Group 4 - Sihai Visual plans to use up to 500 million yuan of idle funds to purchase low-risk, short-term financial products [14] - Binjiang Group won the land use rights for two plots at a total price of 7.742 billion yuan [16] - Canan Co. received a utility model patent certificate for a needle sheath feeding mechanism [18] Group 5 - David Medical's subsidiary's medical device registration application was accepted by the Zhejiang Provincial Drug Administration [20] - Rejing Bio obtained 30 overseas qualification certifications for various in vitro diagnostic reagents and instruments [22] - Jincheng Mining signed a contract worth approximately 21.5 million USD for infrastructure support at a Zambian mine [24] Group 6 - Baiyun Mountain's subsidiary received approval for clinical trials of a new herbal tea product [26] - Hunan Haili successfully acquired land use rights for two plots in Yongxing County [28] - Nanshan Aluminum's subsidiary was listed on the Hong Kong Stock Exchange [30] Group 7 - Jinghua New Materials' application for a simplified procedure to issue shares was accepted by the Shanghai Stock Exchange [32] - Ningbo Construction filed a lawsuit for overdue project payments totaling 112 million yuan [34] - Tiantong Co. received a government subsidy of 47.52 million yuan [36] Group 8 - Zhongqi Co. appointed Zhang Zipeng as the new general manager [38] - Ruihu Mold reported a net profit of 350 million yuan, up 73.20% year-on-year, with total revenue of 2.424 billion yuan [40] - Mega Chip reported a net profit of 211 million yuan, a year-on-year increase of 26.30%, with total revenue of 2.139 billion yuan [42] Group 9 - Shenhuo Co. reported a net profit of 4.307 billion yuan, a decrease of 27.07% year-on-year, with total revenue of 38.373 billion yuan [44] - Feikai Materials plans to acquire 100% of JNC Suzhou and related patents for a total consideration of 3.7 billion yuan [46] - Junpu Intelligent announced that its major shareholders committed not to reduce their holdings for 12 months [48] Group 10 - Yaxing Anchor Chain confirmed that its production and operations are normal amid market interest in marine economy concepts [50] - Guangzhou Development plans to invest 5.612 billion yuan in a coal power environmental replacement project [52] - Ruihu Mold intends to issue convertible bonds to raise up to 880 million yuan for various projects [54]